2019
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma
Natarajan E, Auerbach C, Cheron R, Pashankar F. Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e659-e661. PMID: 31259823, DOI: 10.1097/mph.0000000000001544.Peer-Reviewed Original ResearchConceptsRecurrent hepatoblastomaIfosfamide/carboplatin/etoposide chemotherapyLong-term disease-free survivalCarboplatin/etoposide chemotherapyDisease-free survivalLimited treatment optionsAdjuvant chemotherapySecond relapseEtoposide chemotherapyFirst relapseMultiple relapsesSurgical resectionPoor prognosisTreatment optionsMetastatic hepatoblastomaHepatoblastomaRelapseChemotherapyIrinotecanChildrenRemissionResectionPostresectionPatientsPrognosis
2012
Children's Oncology Group's 2013 blueprint for research: Rare tumors
Rodriguez‐Galindo C, Krailo M, Frazier L, Chintagumpala M, Amatruda J, Katzenstein H, Malogolowkin M, Spector L, Pashankar F, Meyers R, Tomlinson G, Committee O. Children's Oncology Group's 2013 blueprint for research: Rare tumors. Pediatric Blood & Cancer 2012, 60: 1016-1021. PMID: 23255219, PMCID: PMC4304764, DOI: 10.1002/pbc.24428.Peer-Reviewed Original ResearchConceptsGerm cell tumorsCell tumorsRare cancersChildren's Oncology Group's 2013 blueprintInternational phase 3 clinical trialsPhase 3 clinical trialsEvidence-based definitionIntraocular retinoblastomaAdvanced carcinomaRisk stratificationInfrequent malignancyRare tumorClinical trialsClinical studiesLiver tumorsTumorsBiologic studiesChildrenCancerRetinoblastomaCarcinomaMalignancyHepatoblastomaYearsTrials